drugset / Trial / NCT00260052

Erythropoietin Effects After Traumatic Brain Injury

NCT00260052

Phase 2/3 Withdrawn Medical College of Wisconsin
NaSingle-groupDouble-blindTreatment

Summary

To determine if the early administration of erythropoietin to patients sustaining traumatic brain injury will reduce secondary brain injury.

Timeline

Start
2003-07
Primary completion
2010-01
Completion
2010-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 40000 iu Intravenous